stockrowMirum Pharmaceuticals, Inc.
MIRM Healthcare Biotechnology
Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024.
- Revenue
- +39.6%
- EPS
- −1,136.8%
- Free cash flow
- −114.2%
- Total debt
- +136.4%
Quarter to September 2026, against a year earlier
Follow MIRM
Alert me
Mirum Pharmaceuticals, Inc. (MIRM) EBITDA
Mirum Pharmaceuticals, Inc.'s EBITDA for fiscal 2025 was $3.8M, compared with −$62.3M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$867.1M. Over the past ten years it has ranged from −$172.8M (fiscal 2021) to $3.8M (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 4 consecutive fiscal years. Mirum Pharmaceuticals, Inc. ranks 589th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $3.8M | — |
| FY2024 | −$62.3M | — |
| FY2023 | −$97.2M | — |
| FY2022 | −$128.0M | — |
| FY2021 | −$172.8M | — |
| FY2020 | −$103.7M | — |
| FY2019 | −$54.7M | — |
| FY2018 | −$17.4M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | −$52.0M | — |
| Jun 2026 | −$34.9M | — |
| Mar 2026 | −$782.1M | — |
| Dec 2025 | $1.9M | (78.67%) |
| 28 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | $191.8M |
| LGND Ligand Pharmaceuticals Incorporated compare | $57.3M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$118.6M |
| ORKA Oruka Therapeutics, Inc. compare | −$158.0M |
| KOD Kodiak Sciences Inc. compare | −$220.8M |
| CGON CG Oncology, Inc. compare | −$250.7M |
| IMVT Immunovant, Inc. compare | −$565.6M |
| IONS Ionis Pharmaceuticals, Inc. compare | −$579.9M |
| MIRM Mirum Pharmaceuticals, Inc. | −$867.1M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on MIRM
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement